Maarten Meulenbelt and Helmut Brokelmann explore the practical implications of the long-awaited ruling.
On 6 October, the European Court of Justice handed down its long-awaited judgment in the Spanish “dual pricing” case regarding GlaxoSmithKline’s Spanish policy of charging different prices for medicines, depending on whether they were sold in Spain or parallel traded to higher-priced countries such as the UK1,2...
Please login to read the full article.
